Online inquiry

IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5812MR)

This product GTTS-WQ5812MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Kidney transplant rejection, Psoriasis, Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5812MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3941MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ693MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ11781MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ2298MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ14534MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ7446MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ2042MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ7519MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW